Date: January 29, 2019 at 10AM ET (7AM PT)

Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.

Who should attend:

• Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
• Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.

Overview:

Integrating Octet into Early Antibody Discovery Workflows

Colby Souders, Chief Scientific Officer, Abveris

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.

Date: December 4, 2019 at 11AM ET (8AM PT)

Please join Sartorius and Abveris for an exclusive webinar featuring Tracey Mullen, Chief Operating Officer of Abveris, who will review an antibody discovery campaign targeting a glycoprotein for induction of apoptosis. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.

Who should attend:

• Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
• Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.

Interested, but have a scheduling conflict? Click here to register and receive an on-demand link to watch later.

About the webinar:

The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.

Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt iQue platform will be detailed.

Date: November 13, 2019 at 2PM ET (11AM PT)

• Rapid reagent generation timelines
• Maximal epitope coverage with DiversimAb technology
• Highly sensitive specificity screening
• Identification of high-affinity mAbs
• Neutralizing and non-neutralizing mAbs
• Flexible deliverable strategies
• All work done in the USA

Interested, but have a scheduling conflict? Click here to register, and a video link will be sent after the webinar finishes.